Phio Pharmaceuticals Corp.
Clinical-stage biotech developing immuno-oncology therapeutics using RNAi technology.
PHIO | US
Overview
Corporate Details
- ISIN(s):
- US74979C5013 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 411 SWEDELAND ROAD, 19406 KING OF PRUSSIA
- Website:
- https://phiopharma.com/
- Sector:
- Manufacturing
Description
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing immuno-oncology therapeutics. The company's proprietary INTASYL technology is a self-delivering RNA interference (RNAi) platform that utilizes small interfering RNA (siRNA) to silence genes. This process is designed to enhance the ability of the body's immune cells to recognize and kill cancer cells. Phio's development pipeline is focused on treatments for solid tumors, with key initiatives in cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its lead clinical compound is PH-762.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Phio Pharmaceuticals Corp. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Phio Pharmaceuticals Corp.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Phio Pharmaceuticals Corp. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
